Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Cyclophosphamide 17 fludarabine 13 Dexamethasone 12 Cisplatin 12 Rituximab 10 Gemcitabine 9 Paclitaxel 8 Bendamustine Hydrochloride 8 Lenalidomide 7 Decitabine 7 Cytarabine 7 Carboplatin 7 fludarabine phosphate 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Etoposide 6 Bortezomib 6 Radiotherapy 5 Injections 5 Azacitidine 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Drug Therapy 4 Bevacizumab 4 Antilymphocyte Serum 4 venetoclax 3 pomalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × TQ-B3525 × Clear all

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡